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ABSTRACT Aiming to understand, at the molecular level, why oseltamivir (OTV) cannot be used for inhibition of human
inﬂuenza neuraminidase subtype N1 as effectively as for subtypes N2 and N9, molecular dynamics simulations were carried out
for the three complexes, OTV-N1, OTV-N2, and OTV-N9. The three-dimensional OTV-N2 and OTV-N9 initial structures were
represented by the x-ray structures, whereas that of OTV-N1, whose x-ray structure is not yet solved, was built up using the
aligned sequence of H5N1 isolated from humans in Thailand with the x-ray structure of the N2-substrate as the template. In
comparison to the OTV-N2 and OTV-N9 complexes, dramatic changes were observed in the OTV conformation in the OTV-N1
complex in which two of its bulky side chains, N-acethyl (NHAc) and 1-ethylproxy group (OCHEt2), were rotated to adjust the
size to ﬁt into the N1 catalytic site. This change leads directly to the rearrangements of the OTV’s environment, which are i),
distances to its neighbors, W-178 and E-227, are shorter whereas those to residues R-224, E-276, and E-292 are longer; ii),
hydrogen bonds to the two nearest neighbors, R-224 and E-276, are still conserved in distance and number as well as
percentage occupation; iii), the calculated ligand/enzyme binding free energies of 7.20, 13.44, and 13.29 kcal/mol agree
with their inhibitory activities in terms of the experimental IC50 of 36.1–53.2 nM, 1.9–2.7 nM, and 9.5–17.7 nM for the OTV-N1,
OTV-N2, and OTV-N9 complexes, respectively; and iv), hydrogen-bond breaking and creation between the OTV and
neighborhood residues are accordingly in agreement with the ligand solvation/desolvation taking place in the catalytic site.
INTRODUCTION
The avian inﬂuenza A virus (H5N1) is highly pathogenic and
has been shown to cross the species barrier and infect hu-
mans. Since its ﬁrst emergence in Hong Kong in 1997 (1),
the virulent H5N1 infections have caused many human
deaths in various countries in Asia and Europe during the
past few years. These events have led to global concern
about a worldwide pandemic due to the possibility of anti-
genic shift allowing human-to-human transmission.
The inﬂuenza A virus is a negative stranded RNA virus.
Its surface contains two membrane glycoproteins, hemag-
glutinin (HA) and neuraminidase (NA) (2). The HA functions
as the receptor-binding and membrane fusion glycoprotein
in cell entry, whereas the NA functions as the receptor-
destroying enzyme by cleaving the a-ketosidic linkage be-
tween terminal sialic acid and an adjacent sugar residue (3).
Inﬂuenza virus HA and NA are both glycosylated proteins,
but the terminal sialic acids are released by the enzymatic
activity of NA. The virus is further classiﬁed into subtypes
based on i), the subtype of the glycoproteins HA and NA
present on the virus, and ii), ability of the virus to cause
disease. Currently, 15 HA subtypes (H1–H15) and nine NA
subtypes (N1–N9) have been identiﬁed for the inﬂuenza A
virus (4).
Because of the essential role of NA in inﬂuenza replication
and its highly conserved active site, the NA inhibitors were
rationally designed to block this active site of the inﬂuenza
virus. For the treatment or prophylaxis of inﬂuenza infec-
tions, the NA inhibitors are a new class of antiinﬂuenza
drugs that have antiviral activities against a broad range of
inﬂuenza viruses. Several potent and speciﬁc inhibitors of
the NA enzyme have been developed through structure-
based rational drug design, and two inhibitors, zanamivir
(Relenza) and oseltamivir (OTV) (Tamiﬂu), have been
approved for human use (5,6).
Many crystal structures of an inﬂuenza virus complexed
with their substrate and inhibitors have been determined
(7–10). Structure analysis of the NA enzyme demonstrated
that there are several invariant residues which form part of an
active site center. Some of these residues interact directly
with the substrate (functional residues) and others scaffold
for the functional residues (framework residues) (11). These
residues include three arginines at positions 118, 292, and
371. The x-ray structures of N2 and N9 complexed with
substrate and inhibitor show that these three residues form
hydrogen bonds in the same manner with the carboxylate
group of the sugar substrate and side chain of the inhibitor
(2,7,9). Other importance residues are E-276 and E-119,
which were observed to form hydrogen bonds with the sub-
strate (2). It was also reported that interactions between
zanamivir or OTV and the residues in the NA active center
are similar to those with the natural substrate (2). Although
the active sites of N2 and N9 are highly conserved, the
inhibitory activity of OTV leads to the mean IC50 of 1.9–2.7
nM and 9.5–17.7 nM, respectively (12).
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A key question is why NA subtype N1 has a mean IC50 of
36.1–53.2 nM, signiﬁcantly higher than those of N2 and N9
(12). Unfortunately, the x-ray structure of the OTV-H5N1
complex is not yet solved. The only information helping to
understand this fact is the proposal of Moscona (13) based on
the x-ray structure of OTV and zanamivir complexed with
NA N9. The active site of N1 was proposed to change its
shape to accommodate the bulky side chain of OTV, whereas
such change is not required for zanamivir. This rearrange-
ment involves the rotation of E-276 and its bonding to R-224
(13).
To provide an answer to the above question, it is our inten-
tion to investigate structural, dynamic, and thermodynamic
properties as well as solvation of the three NA subtypes, N1,
N2, and N9, complexed with OTV using molecular dynam-
ics (MD) simulations. Here, the initial structure of the OTV-
N1 complex was built up using the aligned sequence H5N1
isolated from humans in Thailand and the x-ray structure of
the N2-substrate as the template.
COMPUTATION METHODS
Validation of the N1 model
The sequence of the human inﬂuenza NAN1, which is the highly pathogenic
H5N1 A virus isolated during the 2004 inﬂuenza outbreaks in Thailand, was
taken from Genbank LOCUS ID AAS89006 (A/Thailand/3(SP-83)/2004).
This sequence consists of 449 amino acids. Currently, the crystal structure of
the N1 protein from H5N1 is not yet solved. However, the three-dimensional
(3D) structure of N1 can be modeled based on the available crystal struc-
tures. In this study, the crystal structure of N2 complexed with substrate (Pro-
tein Data Bank (PDB) code 2BAT, 2.0-A˚ resolutions) and N9 complexed
with OTV (PDB code 2QWK, 1.8-A˚ resolutions) were selected as the
template. Note that the sequences of N2 and N9 contain 388 and 387 amino
acids, respectively. The N1, N2, and N9 sequence alignment was performed
using the homology module in the InsightII program (Accelrys, San Diego,
CA). The ﬁnal alignment was shown in Fig. 1. The N1/N2, N1/N9, and N2/
N9 identities were 46%, 49%, and 48%, respectively.
Three 3D models of N1 were built up using the sequence alignments and
the atomic coordinates of the N2-substrate, N9-OTV, and both structures.
They are, for simplicity, named N1–(N2), N1–(N9), and N1–(N2, N9),
respectively. The Needleman-Wunsch algorithm (14) was used for pairwise
alignment to identify the correspondence region. The scores were obtained
for each pair of amino acid in the sequences, i.e., gaps can be placed in the
proper locations and high scores can be yielded for good matches. The
coordinates of the structurally conserved regions (SCRs)—in which amino
acid sequences in the template and the model are identical—of the template
were copied to be those of the model. For the similar SCRs, only the back-
bone coordinates were replicated and the side-chain atoms were added in a
manner that preserves the model protein’s residue type. The coordinates for
the loop or variable regions were generated by ﬁnding peptide segments in
other proteins that ﬁt properly into the model’s spatial environment.
Superimpositions between the three models, N1–(N2)//N1–(N9), N1–
(N2)//N1–(N2,N9), and N1–(N9)//N1–(N2,N9), were performed. The corre-
sponding root mean-square deviations (RMSDs) are 1.46, 1.39, and 1.41 A˚,
respectively. Inconsistent with the percentage identity between the three
sequences mentioned above, the RMSD values indicate that the three 3D
models do not differ signiﬁcantly.
FIGURE 1 Sequence alignment of N1 (A/Thailand/3(SP-83)/2004) with N2 (PDB code 2BAT) and N9 (PDB code 2QWK). The N1 protein sequence used
in this study is from the highly pathogenic human H5N1 A virus isolated during the 2004 inﬂuenza outbreak in Thailand.
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From the characterization of the 1918 Spanish inﬂuenza virus (H1N1)
NA gene, it was shown that this N1 protein sequence was placed within and
near the root of the avian sequence, N2. Those sequences share many
characteristics with both mammalian and avian viruses. In that study, the
authors suggest that it is possible to align the N1 sequence with N2 subtype
and examine the N2 antigenic site for evidence of drift in N1 (15). With
these reasons, the model built from N2, N1–(N2), was chosen to represent
NA subtype N1 and used for MD simulations. The ﬁnal 3D structure of the
selected model superimposed with the N2 template was displayed in Fig. 2.
Protein preparation for MD simulations
The x-ray structure of N9-OTV (OTV-N9) used for MD simulation was
taken from the PDB. To prepare the OTV-N1 and OTV-N2 complexes,
superimpositions of the following pairs were performed, N1 (model) with
OTV-N9 and N2 (x-ray structure excluded substrate) with OTV-N9. The N9
enzyme coordinates were, then, removed and the OTV-N1 and OTV-N2
were, then, obtained. All missing hydrogens of the protein were added using
the LEaP module in the AMBER 7 software package (16).
The starting structure and force ﬁeld parameters for the inhibitor were
obtained as follows. Hydrogens were added to the x-ray coordinates of OTV
(2QWK) by taking into account the hybridization of the covalent bonds.
Geometric optimization was subsequently performed at the Hartree-Fock
level with 6-31G** basis functions to adjust the bond lengths involving
hydrogens. Then, the restrained electrostatic potential ﬁtting procedure was
employed to calculate partial atomic charges of the inhibitor (17). Force ﬁeld
parameters of the inhibitor were assigned based on the atom types of the
force ﬁeld model (18). Gaussian 98 (19) was used to optimize the molecular
structure, generate electrostatic potentials, and calculate ab initio energies.
Partial charge generation and assignment of the force ﬁeld were performed
using the Antechamber suite (20).
To incorporate the solvent and counterions under consideration, each
system was solvated with 10 A˚ of the TIP3P water model (21) and
neutralized by the counterions using the LEaP module. The crystallographic
water molecules were also kept in the 78 3 86 3 80 simulation box. This
leads to total atoms of 43998, 43905, and 41572 for the OTV-N1, OTV-N2,
and OTV-N9, respectively.
Molecular dynamics simulations
Three MD simulations were performed for the OTV-N1, OTV-N2, and
OTV-N9 complexes, where their initial structures were described above. En-
ergy minimization and MD simulations were carried out using the SANDER
module of AMBER 7 (16) with the Cornell force ﬁeld (18). The periodic
boundary condition with the NPT ensemble was employed. A Berendsen
coupling time of 0.2 ps was used to maintain the temperature and standard
pressure of the system (22). The SHAKE algorithm (23) was applied to
constrain all bonds involving hydrogens. The simulation time step of 2 fs
was used. All MD simulations were run with a 12-A˚ residue-based cutoff for
nonbonded interactions and the particle mesh Ewald method was used for an
adequate treatment of long-range electrostatic interactions (24). The simu-
lation steps consist of thermalization, equilibration, and production phases.
Initially, the temperature of the systemwas gradually heated from 0K to 298K
during the ﬁrst 60 ps. Then, the system was maintained at 298 K until MD
reached 1 ns of the simulation. Finally, the production phase started from 1 ns
to 2 ns of the simulation. The convergence of energies, temperature, pres-
sure, and global RMSD was used to verify the stability of the system.
The MD trajectory was collected every 0.2 ps. Analysis of all MD
trajectories, i.e., RMSD, distances, torsion angles, etc., was carried out using
the CARNAL and Ptraj modules of AMBER 7. The geometry and stereo-
chemistry of the protein structure were validated using PROCHECK (25).
Graphic visualization and presentation of protein structures were done using
RasMol, Swiss-Pdb Viewer (26), WebLab Viewer (Accelrys), and Mol-
Script (27).
The binding free energy (DGbinding) calculations
In general, the free energy of the inhibitor binding, DGbinding, can be
obtained from the difference between the free energy of the receptor-ligand
complex (Gcpx) and the unbound receptor (Grec) and ligand (Glig) as follows:
DGbinding ¼ DGcpx ¼ Gcpx  ðGrec1GligÞ: (1)
The MM/PBSA approach calculates DGbinding on the basis of a thermo-
dynamic cycle. Therefore, Eq. 1. can be approximated as
DGbinding ¼ DEMM  TDS1DGsol; (2)
where DEMM is related to the enthalpic changes in the gas phase upon bind-
ing and is obtained from molecular mechanics van der Waals and elec-
trostatic energies, TDS involves the entropy effect, and DGsol is the free
energy of solvation. Then DGsol is composed of the electrostatic and non-
polar contributions (28), and therefore can be expressed as
DGsol ¼ DGPB1DGSA; (3)
where DGPB was calculated using a continuum solvent model with a
Poisson-Boltzmann solution (29), and DGSA is estimated from the solvent-
accessible surface area (SASA) (30). The DGbinding was obtained using the
MM/PBSAmodule in the program AMBER 7, which interfaces the program
DelPhi 4 (31). To calculate electrostatic free energy of solvation, the grid
resolution of 0.33 A˚ with the boundary conditions of Debye-Huckel po-
tentials was employed. Atomic charges were taken from the Cornell force
ﬁeld (18). The water and protein dielectric values were set to 80 and 1,
respectively. The SASA was calculated using a 1.4-A˚ probe radius. Atomic
radii were taken from the PARSE parameter set (30). The nonpolar free
FIGURE 2 3D structure of N1 modeled according to the template of
2BAT and the crystal structure of N2 complexed with the substrate (sialic
acid) (a). The NA enzyme is shown in ribbon, where the models N1 and N2
are colored in green and color by element, respectively. The substrate is
presented in yellow. The two-dimensional structures of the substrate (sialic
acid) (b) and OTV (c) are also displayed.
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energy of solvation was obtained by 0.005423 SASA1 0.92 kcal/mol (30).
In the study, the contribution of the entropy (TDS) was not included. An
estimation of the entropy effect from normal mode analysis requires high
computational demands. The entropic difference, among the three systems,
should be very small because all system models, NA subtypes N1, N2, and
N9 complexed with OTV, are almost similar. In addition, interpretation will
focus only on the relative values of the binding free energy.
RESULTS AND DISCUSSION
Overall enzyme and inhibitor structures
RMSDs with respect to the initial conﬁguration for the over-
all structure of NA and OTV were separately calculated and
plotted in Fig. 3. Substantial changes were observed for
the OTV-N1 complex, where the RMSD of the enzyme
increases slowly during the ﬁrst;700 ps, whereas that of the
inhibitor raises rapidly at ;1 ns. No signiﬁcant difference
was found for the RMSDs of the other two systems, OTV-N2
and OTV-N9.
Changes of the oseltamivir structure
Detailed evaluations were focused on the changes of the
molecular structure of OTV in the OTV-N1 complex (Fig.
3 b). Structure changes were monitored in terms of torsional
angles, tor1–tor4, deﬁned, respectively, by the following sets
of four atoms, C9-C2-C1-O1, C4-C5-N1-C6, C5-C8-O4-C10,
and C8-O4-C10-C12 in Fig. 4 a. The plots were for all three
systems, evaluated after equilibration, at 1.0 ns. The results
are compared in Fig. 4, b–e. Note that all torsional angle
plots show sharp peaks, indicating that the side chains were
rotated only in a narrow range around their preferential
conﬁgurations.
Considering theCOO side chain of OTV (see Fig. 4 a),
tor1 for the three systems, the OTV in N1, N2, and N9 ap-
pears at almost the same angle, 2 (Fig. 4 b). This means that
theCOO group was observed to lie almost in the ring plane.
Dramatic changes were detected in tor2–tor4 of OTV in
the NA N1 compared with the initial conformation of OTV,
whereas such changes were not found for the N2 and N9
complexes. The tor2 angle in OTV-N2 and OTV-N9 appears
between 100 and120 (Fig. 4 c), indicating that the C5 -
N1 bonds (see the NHAc group in Fig. 4 a) of the OTV in
the two complexes were located above the ligand’s plane and
slightly tilted, by 10–30, to the OCHEt2 group. The tor3
angle of 92 for both systems (Fig. 4 d) implies that the C8-
O4 bond (see Fig. 4 a) lies perpendicular to the ligand plane.
In addition, the detected values of tor4 for both systems at
162 (Fig. 4 e) leads to the conclusion that the end of this
side chain points backward to the OTV molecular plane.
In comparing the OTV-N1 with the OTV-N2 and OTV-N9
systems, a different situation was observed for the confor-
mation of OTV in the OTV-N1 complex in which the tor2–
tor4 angles were turned by 40–60 (from 100 or 120
to 160), 55 (from 92 to 147), and 56 (from 162
to 98), respectively. Changes of the tor2 and tor3 angles
indicate the rotation of the C5-N1 bond in the direction ap-
proaching the OCHEt2 group and rotation of the C8-O4
bond in the direction toward the COO side chain (see
Fig. 4 a), respectively. Interestingly, the tor4 angle of OTV-N1
was turned backward, from 162 to 98 (Fig. 4 e). This
means that the end of the OCHEt2 side chain, deﬁned by
the O4-C10 bond, for the three systems points with the same
angle to the molecular plane.
In conclusion, changes of the OTV structure in the NA N1
pocket can directly affect its interaction with the enzyme as
well as the structure of its environment, solvation, and
nearest enzyme residues (see details in the next sections),
whereas this is not the case for OTV in N2 and N9.
Changes of the neuraminidase cavity
As mentioned earlier, changes of the OTV structure (rotation
of tor2 – tor4 as shown in Fig. 4) can directly affect the
interaction, position, and orientation of the neighboring res-
idues in theNApocket. To visualize and quantify such effects,
distances between the atoms of OTV and its neighboring res-
idues,R-118,R-152,W-178,R-224, E-227,E-276, andR-292,
were measured for the three systems and plotted in Fig. 5.
Effects of the rotation of the OTV side chain can be clearly
seen from this plot. Compared with OTV-N2, which was
used as the template in building up the initial OTV-N1 struc-
ture by homology modeling, changes of the OTV confor-
mation do not affect the positions of the R-118 and R-152
residues (Fig. 5, b and c). Rearrangements of the N1’s active
site around the NHAc and the OCHEt2 groups were
signiﬁcantly observed to accommodate the OTV’s bulky
FIGURE 3 RMSD plots of protein back-
bone atoms (a) and all atoms of OTV (b)
with respect to simulation time.
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side chains. Rotation of the NHAc side chain (tor2 in Fig.
4 a) in the direction to the OCHEt2 group shifts the W-178
(Fig. 5 d) and E-227 (Fig. 5 f) closer to the OTV by more
than 2 A˚. Consequently, the R-224, E-276, and R-292 resi-
dues were repelled by the bulky OCHEt2 group to move
away by more than 1 A˚ (Fig. 5, e, g, and h). The above
ﬁndings may be one of the important reasons OTV is less
susceptible to human inﬂuenza NA subtype N1 than those
in N2 and N9. The importance of R-292 in OTV-N2 and
OTV-N9 is signiﬁed by the existence of the mutant strain
R-292K (32).
An interaction between the R-224 and E-276 residues in
the neighborhood of the OTV molecule was found indirectly
from the x-ray structure of the NA N9 complexed with OTV
(33). With the distances shown in Table 1 and the confor-
mation shown in Fig. 6 a, this suggested clearly that two
hydrogen bonds were formed. Therefore, this type of binding
was supposed to play a role either in stabilizing the enzyme
structure or in the catalytic process.
To monitor this event for the NA N9 in solution as well as
those of the N1 and N2 subtypes, hydrogen bonding between
the two residues was analyzed using the CARNALmodule in
AMBER7with the following criteria: i), the distance between
proton donor (D) and acceptor (A) atoms was#3.5 A˚, and ii),
the D-H. . . .A angle was $120. The results are summarized
in Table 1. The corresponding conﬁgurations for the three
systems, aswell as that of the x-ray data, are depicted in Fig. 6.
Effects of the rotation of the side chains of OTV (tor2–
tor4 in Fig. 4) in the OTV-N1 complex can be seen in terms
of the R-224–E-276 binding shown in Table 1 and Fig. 6.
The position and orientation of the R-224 and E-276 residues
in the crystallographic and liquid phases are noticeably dif-
ferent. In the solution, the numbers of detected hydrogen
bonds are three for OTV-N9 and one for OTV-N1 and
OTV-N2, whereas the x-ray structure has two hydrogen
bonds. This observation indicates destabilization in the vi-
cinity of the NA N1 and N2 pockets in comparison with that
of N9, both in solid and liquid phases.
Interestingly, the positions of R-224 and E-276 in the
OTV-N1 complex were observed to shift by more than 1 A˚
away from the OTV molecule (Fig. 5, e and g) in comparison
with OTV-N2. However, the relative orientation between the
FIGURE 4 Deﬁnition of OTV’s tor-
sional angles, tor1–tor4 (a) and their distri-
butions, (b–e), in the OTV-N1, OTV-N2,
and OTV-N9 complexes, sampling after
equilibration, at 1.0 ns.
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two residues remains unchanged, i.e., distances as well as
numbers and percentage of hydrogen-bond occupation of the
two systems are very similar (Table 1). This conﬁrms the
previous reports that proposed that the active site of the NA
is highly conserved (11).
Taking into account the structural data summarized above,
the OTV structure does not ﬁt well into the NA N1 cavity,
leading to the rotation of its side chain in the OTV-N1 com-
plex. This directly affects its binding with the neighboring
residues in the pocket of the NA. Consequently, the OTV’s
side-chain rotation was found to signiﬁcantly inﬂuence
the position and orientation of the ﬁve nearest neighbors,
W-178, R-224, E-227, E-276, and R-292. The movements of
E-276 and R-224 residues appear, in agreement to some
degree with the proposal by Moscona (13), to be the source
of OTV resistance for the NA subtype N1.
The molecular mechanism of NA resistance to OTV was
proposed by Moscona (13). The NA active site must go
FIGURE 5 Distance to NA residues lo-
cated in the neighborhood of the OTV in the
OTV-N1, OTV-N2, and OTV-N9 systems.
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through a rearrangement to change its shape to accommodate
the bulky side chain of OTV, whereas such a change is not
required for zanamivir. This rearrangement involves the
rotation of the E-276 residue and its bonding to R-224. The
mutations R-292K,N-294S, andH-274Y inhibit this rotation,
resulting in resistance to OTV. AsMoscona did not state how
themolecular structures of both complexes were obtained, we
assume this proposed mechanism to be derived from infor-
mation from the x-ray structures of OTV and zanamivir
complexed with NA N9. In our work, such rearrangements in
the NA N1, N2, and N9 pockets as well as dynamical
properties and solvent effects were additionally quantiﬁed.
Solvation structure and oseltamivir-enzyme
hydrogen bonding
To monitor the ligand’s solvation, especially its changes due
to the rotation of the side chains of OTV (tor2–tor4 in Fig. 4)
and radial distribution function (RDF, gxy(r))—the proba-
bility of ﬁnding a particle of type x in a sphere of radius r
around the particle of type y—from acceptor atoms of OTV
(O1, O2, O3, O4, N1, and N2 as labeled in Fig. 4 a) to an
oxygen atom of water, were evaluated for the three systems
and plotted in Fig. 7. In addition, ligand-enzyme hydrogen
bonding was analyzed using the same criteria as applied for
those of the R-224 and E-276 residues (Table 1 and Fig. 6).
The results are summarized in Table 2.
In terms of the solvent accessible area, space around the
inhibitor can be clearly classiﬁed into two zones. No water
was detected to approach the O3, N1, and N2 atoms of OTV
due to the presence of R-152, E-119, D-151, W-178, and
E-227. Those residues were found to form hydrogen bonds
with the O3, N1, and N2 atoms (Table 2), preventing them
from being accessed by water molecules. The radius of the
water-free region is 3–4 A˚ for OTV-N2 and OTV-N9 and
5–6 A˚ for the OTV-N1 system (Fig. 7, c, e, and f).
TABLE 1 Percentage occupations (%) and the corresponding distances (R, in A˚) of direct hydrogen bonding
X-ray OTV-N1 OTV-N2 OTV-N9
Hydrogen bonds R % R % R % R %
NH2/NH1(R-224)–OE1(E-276) 3.69 – 4.73 – 4.26 – 2.90 100
NH2/NH1(R-224)–OE2(E-276) 2.71 – 2.79 100 2.79 99 2.86 100
NE(R-224)–OE1(E-276) 2.81 – 5.94 – 5.68 – 2.79 100
NE(R-224)–OE2(E-276) 3.34 – 3.85 – 3.95 – 4.11 –
Between residues R-224 and E-276 of NA extracted from the x-ray structure of N9 (PDB code 2QWK) and the MD simulations for the OTV-N1, OTV-N2,
and OTV-N9 systems where the atom types were labeled as in Fig. 6.
FIGURE 6 Hydrogen bonds between the two residues
R-224 and E-276 of the NAs extracted from (a) the x-ray
structure of N9 (PDB code 2QWK) and the MD simula-
tions for the (b) OTV-N1, (c) OTV-N2, and (d) OTV-N9
systems.
804 Aruksakunwong et al.
Biophysical Journal 92(3) 798–807
The situation is different for the regions around the O1, O2,
and O4 atoms of OTV where almost all RDFs show a sharp
ﬁrst peak centered at 2.8 A˚ (Fig. 7, a, b, and d) with the
corresponding coordination number, integrated up to the ﬁrst
minimum. A clear conclusion is that those atoms were sol-
vated by forming hydrogen bonding with one water mole-
cule. Characteristics of the plots are fully consistent with the
ligand-enzyme hydrogen-bond formation shown in Table 2.
For example the O1 atom was found to form four hydrogen
bonds with R-292 and R-371 (Nos. 7, 8, 9, and 11 in Table 2)
for the OTV-N2 and OTV-N9 but only one hydrogen bond
(No. 11 in Table 2) for OTV-N1 system. That means that
R-292 in OTV-N1 was shifted apart from the O1 atom, gen-
erating empty space that can accumulate a water molecule to
form a strong hydrogen bond with O1. This leads to a much
higher and sharper ﬁrst peak of the RDF centered at the O1
atom of OTV than those of O2 and O4.
For the O2 atom of OTV, the numbers of detected hy-
drogen bonds are two (with R-118 and R-371, Nos. 1 and 12
in Table 2), four (two with R-118 and two with R-371, Nos.
1, 2, 10, and 12 in Table 2), and two (with R-371, Nos. 10
and 12 in Table 2) for OTV-N1, OTV-N2, and OTV-N9,
respectively. Only in the OTV-N2 system was the hydrogen
bond to R-118 not detected. These are the reasons the ﬁrst
peak of the N2 RDF is lower than those of N1 and N9.
Correspondence between the two sources of data, ligand-
water RDFs, and ligand-enzyme hydrogen bonds, was clearly
observed for the O4 atom, where only one hydrogen bond
with R-152 (Table 2, No. 4) was found only for the OTV-N1
system, i.e., water molecules were prevented from approach-
ing the O4 atom. This leads directly to the ﬂattening of its
RDF up to 4 A˚ (Fig. 7 d). This is not the case for the other
two systems, OTV-N2 and OTV-N9, where the O4 atom was
evidently solvated by a water molecule.
Enzyme/inhibitor interactions
Interactions between OTV and enzymes were analyzed in
terms of binding free energies computed using MM/PBSA
calculations. The results in Table 3 support the above
FIGURE 7 RDFs centered at donor atoms of
OTV (labeled in Fig. 4 a) to oxygen atoms of
water molecules for the three simulated systems,
OTV-N1, OTV-N2, and OTV-N9, evaluated
after equilibration, at 1.0 ns.
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conclusions regarding lower susceptibility of the inhibitor to
the NA subtype N1 in comparison with N2 and N9. The
calculated total binding free energy for OTV-N1 is 7.20
kcal/mol, whereas it is 13.44 kcal/mol and 13.29 kcal/
mol for OTV-N2 and OTV-N9, respectively. These values
agree well with the experimental free energies of 10.2
to 10.0, 12.0 to 11.7, and 11.0 to 10.6 kcal/mol
(converted from the IC50 values of 36.1–53.2 nM, 1.9–2.7
nM, and 9.5–17.7 nM) for OTV-N1, OTV-N2, and OTV-
N9, respectively.
Referred to the calculation details where the entropic term,
TDS, was neglected based on the assumption that the dif-
ference would be small among the three simulated systems
due to their similarity. This was, somehow, supported by the
thermodynamics study of HIV-1 protease complexed with
saquinavir, ritonavir, nelﬁnavir, and indinavir, which show
that the binding entropy for the four drugs are 14.0,11.2,
14.2, and 15.7 kcal/mol, respectively (34). The differ-
ences are relatively small although sizes of the four drugs are
relatively difference. Therefore, the order of the binding free
energy shown in Table 3 for the simulated systems should
not be changed due to the exclusion of the entropic term. In
addition, interpretation will focus only on the relative values
of the binding free energy.
These binding interactions correspond to the biological
activity of the drug toward the various strains of viruses as
can be seen from Table 3. Very strong bindings are observed
for all complexes in the gas phase. However, these interac-
tions are offset by the complex-solvent interaction. Negative
electrostatic and van der Waals interactions for these com-
plexes imply that the binding is mainly of hydrogen-bonding
type, in agreement with our previous conclusion.
CONCLUSIONS
Rotation of the NHAc and OCHEt2 side chains of the
OTV, which leads consequently to the rearrangements of the
N1’s cavity, is a primary source of the lower susceptibility of
the OTV to inﬂuenza NA subtype N1 than to N2 and N9. The
observed data suggest that the size of these two side chains is
reduced in a way that maintains their interactions with the
neighborhood residues of the N1 protein.
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